The market studied is currently being driven by factors, such as rising geriatric population across the world and increasing demand for remote patient monitoring in developing regions. With the increasing geriatric population and prevalence of chronic diseases, there is a growing need to find new ways of improving patient outcomes, increasing access to care, and reducing the cost of medical care. Using remote patient monitoring, which utilizes devices to remotely collect and direct information to a remote diagnostic testing facility for interpretation, the healthcare providers, insurance payers, and the various governments are seeking to alter the way in which care is being delivered, while reducing the cost of care at the same time. Tele-intensive care units have great potential to expand, access, and improve the quality of rural healthcare. It can help reduce burdens for patients, such as travel, to receive specialty care and improve monitoring, timeliness, and communications within the healthcare system. However, in many places, particularly rural areas, the connectivity broadband remains too expensive, unreliable, or simply not available at the speeds required.

The Europe PACS and RIS market is estimated to grow at a CAGR of 7.0% from 2019 - 2027. The market of PACS and RIS in the Europe region is majorly contributed by the Germany. The region is experiencing the robust growth of the market owing to various factors such as government investment in healthcare infrastructure, increasing awareness regarding the medical imaging as well as the benefits associated with implementation of PACS and RIS. The top 10 industry players operating in the market of PACS and RIS across the globe includes McKesson Corporation, General Electric, Fujifilm Holdings Corporation, Koninklijke Philips N.V., Siemens AG, Cerner Corporation, IBM, Novarad, Agfa-Gevaert Group, and INFINITT Healthcare Co., Ltd.

相较于其他行业数据化发展程度，医疗行业在数据积累上有领先优势，医疗数据的类型和规模一直在快速增长，数据爆炸已经让健康医疗进入大数据时代，在打破数据孤岛、提高数据分析技术的同时，亦为相关大数据服务的发展创造了条件。但在数据的应用水平上，医疗行业远远落后于互联网、金融和电信等信息化程度更好的行业，因此健康医疗大数据市场的关注焦点逐渐从前期的数据互通互联走向数据分析应用。

The growth of the global veterinary diagnostic imaging market is currently being driven by various factors, including the rising adoption of companion and livestock animals, increasing animal health expenditure, rising prevalence of animal diseases, and technological advancements in the diagnostic imaging field, among others. There has also been an increasing adoption of pet animals every year. Animal shelters and rescue groups are overflowing with healthy, happy pets just waiting for someone to adopt them and take them home. The primary reason behind this rise in pet adoption is the fact that not only do animals give humans unconditional love, but they have also been proven to be emotionally, psychologically, and physically beneficial to their companions. Caring for a pet animal provides a sense of purpose and fulfillment in one’s day-to-day life and it also reduces the feeling of loneliness, in this era of busy schedules and nuclear families. But adopting an animal comes with the huge responsibility of taking care of it in every possible way, as animals are also being diagnosed with several diseases. That is why the demand for diagnosis of various diseases, injuries, and disorders of these animals is on a significant rise. For example, the recent years have observed a significant rise in the prevalence of cancer in dogs and cats, which directly generates a rise in the need for proper pet cancer diagnosis.

截至目前，全国新型肺炎病确诊病例数已增至74185 例，现有疑似病例5248 例，累计治愈出院病例14376 例，累计死亡病例2004 例。2 月18 日新增治愈患者数量首次超过新增确诊患者数量。

新型冠状病毒肺炎传播力强，潜伏期长，疫情影响范围广。2019 年底发生的新型冠状病毒肺炎疫情目前已在全国31 个省市（自治区）均已出现确诊病例，截止2 月16 日，大陆累计确诊70548 例新冠病毒肺炎病例，已远超2003 年SARS 感染确诊病例最高值5329 例。此次新型冠状病毒肺炎具有传播力强，潜伏期长，疫情影响范围广的特征。

目前国内生物药市场规模已由14 年的618 亿增长至18 年的930 亿，年均复合增速达11%。与全球市场相比，目前生物药（包括类似物）在国内药品市场中占比仍偏低，未来成长潜力巨大。与此同时我国也已成为全球生物类似药在研数量最多的国家，先后有近200 余个生物类似药临床试验申请获得批准，自2019 年2 月国产首个生物类似药汉利康(利妥昔单抗注射液)正式获批上市以来，目前国内已有四个生物类似物产品陆续获批（利妥昔单抗、阿达木单抗及贝伐珠单抗），随着高性价比的国产生物类似物品种陆续上市，将极大提高国内生物药市场渗透率和患者可及性。

截至2020年2月18日，在柳叶刀（the Lancet）、新英格兰（NEJM）等顶级杂志中，已有多篇关于2019-nCoV的学术论文发表或上线。分别讨论了2019-nCoV的基因序列、病毒分类，临床案例，流行病学分析及启示等。

The market studied is currently being driven by factors, such as the increasing prevalence of sepsis, the growing incidence of hospital-acquired infections, rise in the number of sepsis procedures, and increase in the funding for sepsis-related research activities. Furthermore, similar hospital-acquired infections have been observed across the world and these are boosting the need for proper diagnosis. Hence, the rise in hospital-acquired infections is expected to drive the overall growth of the sepsis diagnosis market, over the forecast period. On the basis of pathogens that cause septicemia, the bacterial sepsis segment holds the largest market share, due to the fact that most of the patients suffering from blood-poisoning diseases are victims of bacterial infection. The most commonly formed bacterial sepsis is gram-negative bacteria.